Vivoryon Therapeutics N.V.
Clinical-stage company developing therapies by targeting protein modifications.
VVY | AS
Overview
Corporate Details
- ISIN(s):
- NL00150002Q7 (+1 more)
- LEI:
- 3912004AMB0KGZXZYJ15
- Country:
- Germany
- Address:
- Weinbergweg 22, 06120 Halle (Saale)
- Website:
- https://www.vivoryon.com/
- Sector:
- Manufacturing
Description
Vivoryon Therapeutics N.V. is a clinical-stage precision medicine company focused on developing first-in-class therapies by targeting post-translational modifications of proteins. The company's scientific approach centers on inhibiting glutaminyl cyclases (QPCT and QPCTL), enzymes that catalyze pyroglutamate formation, a process implicated in the progression of various diseases. Its lead product candidate, varoglutamstat, is an orally administered small molecule QPCT/L inhibitor. Vivoryon is advancing its therapeutic pipeline for patients with inflammatory, fibrotic, and neurodegenerative diseases, with a strategic focus on conditions such as chronic kidney disease.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-09-04 07:28 |
Vivoryon Therapeutics N.V., Halfjaarlijkse financiële verslaggeving
|
English | 1.3 MB | ||
| 2025-08-21 14:00 |
VeonGen Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT)…
|
English | 7.6 KB | ||
| 2025-06-27 07:36 |
Vivoryon Therapeutics N.V. to Present at Upcoming Investor Conferences
|
English | 649.6 KB | ||
| 2025-06-17 07:52 |
Vivoryon Therapeutics N.V. Q1 2025 Financial Results and Operational Progress
|
English | 716.2 KB | ||
| 2025-06-11 07:44 |
Vivoryon Therapeutics N.V. to Report Q1 2025 Financial Results and Operational …
|
English | 650.9 KB | ||
| 2025-06-06 10:30 |
Vivoryon Therapeutics N.V. Presents Meta-analysis Data of VIVIAD and VIVA-MIND …
|
English | 654.5 KB | ||
| 2025-06-05 14:00 |
ViGeneron Rebrands as VeonGen Therapeutics and Announces FDA Rare Pediatric Dis…
|
English | 8.8 KB | ||
| 2025-05-27 07:44 |
Vivoryon Therapeutics N.V. Expands Intellectual Property Portfolio with New U.S…
|
English | 686.4 KB | ||
| 2025-04-29 07:02 |
Vivoryon Therapeutics N.V., Jaarlijkse financiële verslaggeving
|
English | 10.7 MB | ||
| 2025-04-25 07:42 |
Vivoryon Therapeutics N.V. Signs Financing Agreement for up to EUR 15 Million
|
English | 656.2 KB | ||
| 2025-02-11 18:12 |
Vivoryon Therapeutics N.V. to Host Virtual R&D Update with KOL Speakers on Febr…
|
English | 629.7 KB | ||
| 2024-12-10 07:49 |
Vivoryon Therapeutics N.V. Reports Q3 2024 Results and Highlights Progress on V…
|
English | 674.7 KB | ||
| 2024-11-20 17:07 |
Probiodrug announces encouraging results of the Phase 2a SAPHIR Study
|
English | 2.0 MB | ||
| 2024-10-28 07:39 |
Vivoryon Therapeutics N.V. Presents Outstanding Phase 2b Results of Varoglutam…
|
English | 722.2 KB | ||
| 2024-10-11 16:18 |
Vivoryon Therapeutics N.V. Announces Late-breaking Oral Presentation at the Ame…
|
English | 222.8 KB |
Automate Your Workflow. Get a real-time feed of all Vivoryon Therapeutics N.V. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Vivoryon Therapeutics N.V.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Vivoryon Therapeutics N.V. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2022-04-01 | E. Platzer | Executive member | Buy | 123,809 | 1,299,994.50 EUR |
| 2022-04-01 | U. Dauer | Executive member | Buy | 4,761 | 49,990.50 EUR |
| 2020-12-02 | D.J. von der Osten | Executive member | Buy | 20,000 | 112,400.00 EUR |
| 2020-11-30 | M. Schaeffer | Executive member | Other | 3,867 | N/A |
Peer Companies
